{"entity":{"id":"nct07139470","kind":"trial","name":"Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of sacituzumab tirumotecan and anlotinib in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.","summary":"Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer is a phase 1/2, interventional study registered as NCT07139470 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 59 participants, started 2025-08-15 and due to reach its primary completion in 2027-04-15. Interventions recorded: Sacituzumab Tirumotecan + anlotinib. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"* Histologically and/or cytologically confirmed triple-negative breast cancer (TNBC) based on the most recent biopsy or pathological specimen, including:\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07139470","url":"https://clinicaltrials.gov/study/NCT07139470"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["sacituzumab-tirumotecan","anlotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07139470","phase":"1/2","setting":"An Open-label, Single-arm, Multicenter Phase I/II Study of Sacituzumab Tirumotecan (Sac-TMT) Plus Anlotinib in Previously Treated Metastatic Triple Negative Breast Cancer (mTNBC).","sponsor":"Tianjin Medical University Cancer Institute and Hospital","participation":[{"nct":"NCT07139470","source":"https://clinicaltrials.gov/study/NCT07139470","fetchedAt":"2026-10-07T16:55:28.490Z","studySha256":"0c804daa19bab49e1b2fe6bc6809f0bb6511b2fbe0e9c83a47263106020c5625","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2025-08-24","leadSponsor":"Tianjin Medical University Cancer Institute and Hospital","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":59,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2025-08-15","startedType":"estimated","enrolled":59,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07139470/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}